1. Home
  2. PODD vs RDY Comparison

PODD vs RDY Comparison

Compare PODD & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Insulet Corporation

PODD

Insulet Corporation

SELL

Current Price

$145.42

Market Cap

10.2B

Sector

Health Care

ML Signal

SELL

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

SELL

Current Price

$14.69

Market Cap

9.9B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
PODD
RDY
Founded
2000
1984
Country
United States
India
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.2B
9.9B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
PODD
RDY
Price
$145.42
$14.69
Analyst Decision
Buy
Buy
Analyst Count
26
5
Target Price
★ $178.57
$14.40
AVG Volume (30 Days)
1.2M
★ 2.6M
Earning Date
11-04-2026
10-23-2026
Dividend Yield
N/A
★ 0.44%
EPS Growth
N/A
★ N/A
EPS
★ 4.69
N/A
Revenue
★ $2,708,100,000.00
N/A
Revenue This Year
$22.02
$4.57
Revenue Next Year
$11.71
$11.92
P/E Ratio
$32.65
★ $18.67
Revenue Growth
★ 30.73
N/A
52 Week Low
$126.40
$11.36
52 Week High
$354.88
$15.67

Technical Indicators

Market Signals
Indicator
PODD
RDY
Relative Strength Index (RSI) 47.66 67.91
Support Level $141.26 $12.91
Resistance Level $153.33 $15.08
Average True Range (ATR) 7.29 0.27
MACD -0.83 -0.01
Stochastic Oscillator 9.08 73.02

Price Performance

Historical Comparison
PODD
RDY

About PODD Insulet Corporation

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: